0.20Open0.20Pre Close30 Volume0 Open Interest1.00Strike Price866.00Turnover218.80%IV17.32%PremiumJul 19, 2024Expiry Date0.10Intrinsic Value100Multiplier7DDays to Expiry0.16Extrinsic Value100Contract SizeAmericanOptions Type-0.5789Delta1.4147Gamma5.12Leverage Ratio-0.0076Theta-0.0001Rho-2.96Eff Leverage0.0005Vega
Kazia Therapeutics Stock Discussion
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, has recently announced findings from a Phase II/III clinical trial evaluating their novel drug, paxalisib, for the treatment of glioblastoma. Glioblastoma is a highly aggressive and life-threatening brain cancer, representing one of th...
No comment yet